
    
      In a prospective registry prevalent and incident patients diagnosed with group 1 to 5
      pulmonary hypertension will be enrolled. In an integrated biobank body fluid samples will be
      collected at enrollment and sequentially during treatment with targeted drugs for pulmonary
      hypertension.
    
  